An Antiviral Formulation with RNA Dependent RNA Polymerase and Viral DNA gyrase Suppressive Features for The Treatment of Coronaviral & adenoviral Infections

An Antiviral Formulation Consisting of 3 protopanaxatriol-Class glucopyranoside Analouges, A Semi-Synthetic flavonol Glycoside Derivative and an Immuno-modulatory Ginsenoside RG3 Subvariant for The Treatment of Coronaviral & adenoviral Infections via Suppressing DNA Polymerase, RNA Dependent RNA Polymerase and Viral DNA gyrase and Modulating Anti-Inflammatory Cytokines Tnf-Alpha, IL-6, Nf-Kappa B and PGE2 to Suppress Potential Cytokine Storms simultaneously.

Inventors: ERDAL CAN ALKOCLAR & METEHAN YESIL